Details
Stereochemistry | ACHIRAL |
Molecular Formula | CO3.2Al.6Mg.9O.12H2O |
Molecular Weight | 619.9799 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | -2 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O
InChI
InChIKey=BEBILBPAQKONJS-UHFFFAOYSA-L
InChI=1S/CH2O3.2Al.6Mg.12H2O.9O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;;;12*1H2;;;;;;;;;/q;2*+3;6*+2;;;;;;;;;;;;;9*-2/p-2
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Al |
Molecular Weight | 26.9815 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Mg |
Molecular Weight | 24.305 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CH2O3 |
Molecular Weight | 62.0248 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.rlsnet.ru/tn_index_id_12707.htmCurator's Comment: description was created based on several sources, including
https://www.drugs.com/international/algeldrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18362170 | https://www.ncbi.nlm.nih.gov/pubmed/12222737 | https://www.ncbi.nlm.nih.gov/pubmed/9115023 | https://www.ncbi.nlm.nih.gov/pubmed/15479434
Sources: https://www.rlsnet.ru/tn_index_id_12707.htm
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/algeldrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18362170 | https://www.ncbi.nlm.nih.gov/pubmed/12222737 | https://www.ncbi.nlm.nih.gov/pubmed/9115023 | https://www.ncbi.nlm.nih.gov/pubmed/15479434
Algeldrate (Aluminium hydroxide) is the amphoteric inorganic compound used as an antacid in the treatment of Duodenal, Peptic and Stomach Ulcer and some other conditions. Aluminium hydroxide is preferred over other alternatives such as sodium bicarbonate because Al(OH)3, being insoluble, does not increase the pH of stomach above 7 and hence, does not trigger secretion of excess acid by the stomach. Brand names include Alu-Cap, Aludrox, Gaviscon or Pepsamar. It reacts with the excess acid in the stomach, reducing the acidity of the stomach content, which may relieve the symptoms of ulcers, heartburn or dyspepsia. Such products can cause constipation, because the aluminum ions inhibit the contractions of smooth muscle cells in the gastrointestinal tract, slowing peristalsis and lengthening the time needed for stool to pass through the colon. Some such products (such as Maalox) are formulated to minimize such effects through the inclusion of equal concentrations of magnesium hydroxide or magnesium carbonate, which have counterbalancing laxative effects. This compound is also used to control phosphate (phosphorus) levels in the blood of people suffering from kidney failure. Precipitated aluminum hydroxide is included as an adjuvant in some vaccines (e.g. anthrax vaccine). One of the well-known brands of aluminum hydroxide adjuvant is Alhydrogel, made by Brenntag Biosector. Since it absorbs protein well, it also functions to stabilize vaccines by preventing the proteins in the vaccine from precipitating or sticking to the walls of the container during storage. Aluminium hydroxide is sometimes mistakenly called "alum", which properly refers to aluminum potassium sulfate. Vaccine formulations containing aluminum hydroxide stimulate the immune system by inducing the release of uric acid, an immunological danger signal. This strongly attracts certain types of monocytes which differentiate into dendritic cells. The dendritic cells pick up the antigen, carry it to lymph nodes, and stimulate T cells and B cells. It appears to contribute to induction of a good Th2 response, so is useful for immunizing against pathogens that are blocked by antibodies. In the 1960s and 1970s, it was speculated that aluminum was related to various neurological disorders including Alzheimer's disease. Since then, multiple epidemiological studies have found no connection between exposure to aluminum and neurological disorders.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0002548 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18362170 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Alhydrogel Approved UseUnknown |
|||
Primary | Gelusil-Lac Approved UseUnknown |
|||
Primary | Gastracid Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[TNF-alpha secretion by human macrophage-like cells in response to wear particles and its modification by drugs]. | 1999 May |
|
Quartz exposure of the rat lung leads to a linear dose response in inflammation but not in oxidative DNA damage and mutagenicity. | 2001 Apr |
|
Effects of polyethylene and alpha-alumina particles on IL-6 expression and secretion in primary cultures of human osteoblastic cells. | 2002 Feb |
|
Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants. | 2002 Nov |
|
Matrix metalloproteinases MMP-2, -9 and tissue inhibitors TIMP-1, -2 expression and secretion by primary human osteoblast cells in response to titanium, zirconia, and alumina ceramics. | 2004 Jan 1 |
|
Comparison of the response of primary human blood monocytes and the U937 human monocytic cell line to two different sizes of alumina ceramic particles. | 2004 Jul |
|
Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles. | 2005 May |
|
Alumina nanoparticles induce expression of endothelial cell adhesion molecules. | 2008 May 30 |
|
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. | 2012 Apr |
|
Toxicoproteomic analysis of pulmonary carbon nanotube exposure using LC-MS/MS. | 2015 Mar 2 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.rlsnet.ru/tn_index_id_12707.htm
Adults and children over 15 years: 1-2 table (400-800ьп). 4 times a day 1 hour after meals and in the evening before bed or if there is discomfort, epigastric pain, heartburn.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18362170
Bone marrow cells were cultured for 9 d in dendritic cells (DC) culture medium (DC-CM; RPMI 1640 containing GlutaMAX-I; Invitrogen) supplemented with 5% (vol/vol) FCS (Sigma-Aldrich), 50 μ M 2-mercaptoethanol (Sigma-Aldrich), 50 μ g/ml gentamicin (Invitrogen), and 20 ng/ml recombinant mouse GM-CSF (a gift from K. Thielemans, Vrije Universiteit Brussel, Brussels, Belgium). 16 h before harvesting, DCs were exposed either to 10 μ g/ml of OVA, alum (Algeldrate), or OVA-alum suspension.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:57:40 GMT 2023
by
admin
on
Fri Dec 15 17:57:40 GMT 2023
|
Record UNII |
17432CG1KU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 633
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
||
|
WHO-ATC |
A02AD04
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
||
|
WHO-VATC |
QA02AD04
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 193
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB13322
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | |||
|
C010467
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | |||
|
73415812
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | |||
|
454465-31-7
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
ALTERNATIVE | |||
|
m6994
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
12304-65-3
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | |||
|
2841
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | |||
|
27221
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB08071MIG
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | |||
|
C166469
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | |||
|
100000084217
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | |||
|
17432CG1KU
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY | |||
|
17432CG1KU
Created by
admin on Fri Dec 15 17:57:41 GMT 2023 , Edited by admin on Fri Dec 15 17:57:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |